Results for: Norovirus

Oppenheimer initiated coverage on Vaxart Inc. (VXRT), a biotechnology company developing oral vaccines, with an Outperform rating and a $4 price target. The firm is optimistic about Vaxart’s ‘differentiated’ oral vaccine platform, particularly its norovirus and COVID-19 vaccine programs. Vaxart’s potential for commercial success is driven by the lack of approved norovirus vaccines and the company’s leadership in this space.

The Centers for Disease Control and Prevention (CDC) is investigating two separate norovirus outbreaks on cruise ships linked to the United States. The outbreaks on Princess Cruises’ Sapphire Princess and Royal Caribbean International’s Radiance of the Seas have affected 161 passengers and crew members, primarily causing symptoms of diarrhea and vomiting.